UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% ...

UBS initiated coverage of Alvotech (ALVO) with a Buy rating and $18 price target Alvotech is a pure-play biosimilar company, with a ...

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other ...

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

CEO David Joyner highlighted the company's Q4 adjusted EPS of $1.19 and adjusted operating income of $2.7 billion. He introduced 2025 adjusted EPS guidance of $5.75 to $6.00, emphasizing recovery in ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

We spoke recently with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

That’s why one of the most closely watched elements of a company’s earnings report is the guidance it gives for the next ...

The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key ...